Literature DB >> 24176996

Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?

Pierre-Régis Burgel1, Gaetan Deslée, Gilles Jebrak, Graziella Brinchault, Denis Caillaud, Pascal Chanez, Isabelle Court-Fortune, Roger Escamilla, Pascale Nesme-Meyer, Jean-Louis Paillasseur, Thierry Perez, Nicolas Roche.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24176996     DOI： 10.1183/09031936.00162313

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  10 in total

Review 1.  Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?

Authors:  Andrea P Rossi; Erika Zanardi; Mauro Zamboni; Andrea Rossi
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

2.  Inhaled Corticosteroids And Risk Of Tuberculosis In Patients With Obstructive Lung Diseases: A Systematic Review And Meta-Analysis Of Non-randomized Studies.

Authors:  Giorgio Castellana; Marco Castellana; Carlo Castellana; Giuseppe Castellana; Emanuela Resta; Mauro Carone; Onofrio Resta
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-09-26

Review 3.  A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Borja G Cosío; Aurelio Arnedillo; Myriam Calle; Bernardino Alcázar-Navarrete; Cruz González; Cristóbal Esteban; Juan Antonio Trigueros; José Miguel Rodríguez González-Moro; José Antonio Quintano Jiménez; Adolfo Baloira
Journal:  Respir Res       Date:  2017-11-28

4.  Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.

Authors:  Alejandro Casas; Maria Montes de Oca; Ana Mb Menezes; Fernando C Wehrmeister; Maria Victorina Lopez Varela; Laura Mendoza; Larissa Ramírez; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-05-11

5.  Are there specific clinical characteristics associated with physician's treatment choices in COPD?

Authors:  Nicolas Roche; Anestis Antoniadis; David Hess; Pei Zhi Li; Eric Kelkel; Sylvie Leroy; Christophe Pison; Pierre-Régis Burgel; Bernard Aguilaniu
Journal:  Respir Res       Date:  2019-08-20

6.  Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease.

Authors:  Sun Hye Shin; Deog Kyeom Kim; Sang-Heon Kim; Tae Rim Shin; Ki-Suck Jung; Kwang Ha Yoo; Ki-Eun Hwang; Hye Yun Park; Yong Suk Jo
Journal:  J Pers Med       Date:  2022-05-31

7.  Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis.

Authors:  Roland Buhl; Thomas Wilke; Nils Picker; Olaf Schmidt; Marlene Hechtner; Anke Kondla; Ulf Maywald; Claus F Vogelmeier
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-09-22

8.  The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.

Authors:  Guy Brusselle; David Price; Kevin Gruffydd-Jones; Marc Miravitlles; Dorothy L Keininger; Rebecca Stewart; Michael Baldwin; Rupert C Jones
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-15

Review 9.  A review of national guidelines for management of COPD in Europe.

Authors:  Marc Miravitlles; Claus Vogelmeier; Nicolas Roche; David Halpin; João Cardoso; Alexander G Chuchalin; Hannu Kankaanranta; Thomas Sandström; Paweł Śliwiński; Jaromir Zatloukal; Francesco Blasi
Journal:  Eur Respir J       Date:  2016-01-21       Impact factor: 16.671

Review 10.  Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal.

Authors:  Barbara P Yawn; Samy Suissa; Andrea Rossi
Journal:  NPJ Prim Care Respir Med       Date:  2016-09-29       Impact factor: 2.871
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.